文献速递糖尿病

真实世界环境中使用智能胰岛素笔的糖尿病患者治疗依从性与持续葡萄糖监测结果之间的关联

Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting.
PubMed 文献 · Diabetes Care · 2024-01-01

研究基于16个国家3945名成人使用德谷胰岛素和餐时胰岛素智能笔联合CGM的真实世界数据,分析14天周期内漏用胰岛素剂量与血糖控制的关系。每14天漏用1次基础或餐时胰岛素分别与TIR降低2.8%和1.7%相关,漏用2次基础或4次餐时胰岛素可使TIR降低超过5%。智能笔使用与血糖结果正相关。

要点

  • 每14天漏用1次基础胰岛素与TIR降低2.8%相关,漏用1次餐时胰岛素与TIR降低1.7%相关。
  • 每14天漏用2次基础或4次餐时胰岛素可使TIR降低超过5%。
  • 智能胰岛素笔的使用与血糖结局呈正相关。

核心结论

  • 每14天漏用2次基础或4次餐时胰岛素与TIR出现具有临床意义的下降相关。
  • 智能胰岛素笔为了解治疗注射行为提供了有价值的洞察。

研究设计与样本

  • 研究汇总了来自16个国家的3945名成人自我注射德谷胰岛素和餐时胰岛素并使用智能胰岛素笔(NovoPen 6或NovoPen Echo Plus)联合CGM的真实世界数据,数据按14天周期汇总,分析纳入25157个CGM覆盖率≥70%的14天周期。

主要发现

  • 14天内平均漏用基础胰岛素0.2次、餐时胰岛素6.0次。
  • 14天周期内漏用至少1次基础胰岛素剂量的估计概率为17.6%(95%CI 16.5, 18.7)。
  • 每14天漏用1次基础胰岛素与TIR(3.9-10.0 mmol/L)降低2.8%(95%CI -3.7, -1.8)相关,漏用1次餐时胰岛素与TIR降低1.7%(95%CI -1.8, -1.6)相关。
  • 每14天漏用2次基础或4次餐时胰岛素可使TIR降低超过5%。
  • 智能笔使用与血糖结局呈正相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association of insulin injection adherence, smart insulin pen engagement, and glycemic control using real-world data from 16 countries from adults self-administering basal insulin degludec and bolus insulin with a smart insulin pen (NovoPen 6 or NovoPen Echo Plus) alongside continuous glucose monitoring (CGM). RESEARCH DESIGN AND METHODS: Data were aggregated over 14-day periods. Treatment adherence was defined according to the number of missed basal and missed bolus insulin doses and smart pen engagement according to the number of days with data uploads. RESULTS: Data from 3,945 adults, including 25,157 14-day periods with ≥70% CGM coverage, were analyzed. On average, 0.2 basal and 6.0 bolus insulin doses were missed over 14 days. The estimated probability of missing at least one basal insulin dose over a 14-day period was 17.6% (95% CI 16.5, 18.7). Missing one basal or bolus insulin dose per 14 days was associated with a significant decrease in percentage of time with glucose levels in range (TIR) (3.9-10.0 mmol/L), of -2.8% (95% CI -3.7, -1.8) and -1.7% (-1.8, -1.6), respectively; therefore, missing two basal or four bolus doses would decrease TIR by >5%. Smart pen engagement was associated positively with glycemic outcomes. CONCLUSIONS: This combined analysis of real-world smart pen and CGM data showed that missing two basal or four bolus insulin doses over a 14-day period would be associated with a clinically relevant decrease in TIR. Smart insulin pens provide valuable insights into treatment injection behaviors.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Danne TPA, Joubert M, Hartvig NV, et al. Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting. Diabetes Care. 2024. PMID: 38569055. doi:10.2337/dc23-2176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。